LABORATORIES AND RESEARCH

Header

WHERE MEDICAMENTS WITHOUT SIDE EFFECTS ARE PRODUCED

Our production unit is authorized in accordance with international GMP standards. The production, control and storage of products take place in controlled particle contamination rooms, according to the strictest international standards.

As regards low dose medicinal products, the production starts from the mother tincture, a special macerate that can be obtained from plants, buds, biochemical compounds or biological substances, according to the ancient preparation procedures of the traditional Homeopathic Pharmacopoeia.

The mother tincture is gradually and constantly diluted under a laminar flow hood in class 100, usually using a water-alcohol solution as a solvent.

At each dilution a dynamization procedure is performed, i.e., one vertical shaking that transmits physical-chemical specifications to the solution. The activation process is standardized through the use of the SKA (Sequential Kinetic Activation) method, designed and developed by our researchers.

This technique ensures a full bioavailability of the active ingredients and improves their therapeutic properties.

Guna produces pellets, globules and drops for oral use, as well as injectable vials.

The production line is fully automated and produces both mono- and multi-component remedies.

All the qualitative, quantitative and microbiological controls required by the regulations on medicaments are carried out at our perfectly equipped production site. Guna, in an ideal synthesis between tradition and modernity, uses the most advanced scientific and technological breakthroughs in the production of its medicines, to give doctors and patients more and more effective medicaments without side effects, in compliance with the human being’s uniqueness.

In order to improve more and more the efficacy of our medicaments we are continuously developing basic and clinical researches. In the follow you may read some references of the publication supported by GUNA.

PUBLISHED PAPERS

Year

Authors

Journal

Research type

Title

Tested Molecules

2009

Gariboldi S. et al.

Pulmonary Pharmacology & Therapeutics

In vivo

basic

research

Low dose oral administration of cytokines for treatment of allergic asthma.

IL-12

IFN-γ

2012

D’amico L. et al.

Journal of Cancer Therapy

Ex vivo

basic

research

Low Dose of IL-12 stimulates T Cell response in cultures of PBMCs derived from Non Small Cell Lung Cancer Patients.

IL-12

2013

Cardani D. et al.

Gastroenterology Research

In vivo

basic

research

Oral administration of Interleukin-10 and Anti-IL-1 Antibody ameliorates experimental intestinal inflammation.

IL-10

α-IL-1

2014

Radice E.

et al.

International Immunopharmacology

Ex vivo

basic

research

Low-doses of sequential-kinetic-activated interferon-gamma enhance the ex vivo cytotoxicity of peripheral blood natural killer cells from patients with early-stage colorectal cancer. A preliminary study.

IFN-γ

2014

Roberti ML. et al.

Journal of Biological Regulatory & Homeostatic Agents

Clinical Trial

Immunomodulating treatment with low dose Interleukin-4, Interleukin-10 and Interleukin-11 in Psoriasis Vulgaris.

IL-4

IL-10

IL-11

2015

Luchetti P.

Minerva Medica Oftalmologica

Clinical

Trial

Increasing of visual function in patients with retinal atrophy treated with drugs of Low Dose Medicine.

Monocentric retrospective observational study.

NT3

NT4

NGF

2015

Barygina V.

et al

Journal of Dermatological Science

In vitro

Basic research

Treatment with low-dose cytokines reduces oxidative-mediated injury

in perilesional keratinocytes from vitiligo skin.

IL-4

IL-10

b-FGF

β-endorphin

2015

Lotti T.

et al

Journal of

Biological Regulatory

& Homeostatic Agents

Clinical Trial

Vitiligo: successful combination treatment based on oral low dose cytokines and

di­fferent topical treatments.

IL-4

IL-10

Anti-IL-1

b-FGF

2015

Radice E.

et al

Translational

oncology

Ex vivo

Basic research

Enhancement of the immunomodulatory functions of ex vivo-generated dendritic cells from early-stage colon cancer patients by consecutive exposure to low doses of sequential kinetic activated IL-4 and IL-12.

A preliminary study.

IL-4

IL-12

2015

Lotti T.

et al

Der Hautarzt

Clinical Trial

Successful combination treatment for Psoriasis with phototherapy and Low Dose Cytokines. A spontaneous observational retrospective clinical study.

IL-4

IL-10

Anti-IL-1

2015

Tessaro et al.

Journal of Ovarian Research

In vivo

basic

research

Effect of oral administration of low-dose

follicle stimulating hormone on hyperandrogenized

mice as amodel of polycystic ovary syndrome

FSH

 

SUBMITTED PAPERS

Year

Authors

Journal

Research type

Title

Tested Molecules

2015

Galli E. et al.

Submitted

Clinical

Trial

Clinical and immunological evaluation of long-term treatment with Low Dose Medicine in pediatric population affected by chronic Atopic Dermatitis. Experimental randomized double-blind at two stages clinical trial.

IL-12

IFN-γ

2015

Fiorito F. et al

Submitted

Clinical

Trial (veterinary)

Clinical improvement in feline herpesvirus-1 infected cats by oral low doses of interleukin-12 and interferon-gamma.

IL-12

IFN-γ

2016

Migliore A. et al.

Submitted

Clinical Trial

Treatment of Rheumatoid Arthritis with low dose SKA compared to standard treatment.

Anti IL-1

IL-10

IL-4

 

RESEARCH WORKS ON GOING

Year

Authors

Journal

Research type

Title

Tested Molecules

2016

Matucci M. et al.

 

Pilot Clinical Study

Effectiveness of low dose SKA Anti IL-1 and IL-10 in Early Stage Symptomatic Osteoarthritis.

Anti IL-1

IL-10

 

RESEARCH WORKS IN PIPELINE

Year

Authors

Journal

Research type

Title

Tested Molecules

2016

Torta R. et al.

 

Clinical

Trial

Fibromyalgia and low grade inflammation: effectiveness and safety of low dose Interleukin-10 in a double blind randomized placebo controlled clinical trial.

IL-10

2016

Masieri S. et al.

 

Clinical Trial

Effects of low dose SKA Interleukin-10 and TGF-Beta in nasal polyps.

IL-10

TGF-β

2016

De Cicco F. et al.

 

In vivo and in vitro basic research

Efficacy of low dose SKA interleukins and hormones in an animal model and cell cultures of Endometriosis.

Anti IL-1

IL-10

Progesterone